GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Sacubitril / valsartan tablets (Entresto, adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Entresto

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
ENTRESTO: reduced starting dose is not a permanent maintenance cap

The renal subsection changes the initial dose in severe impairment and then retains titration and kidney/potassium monitoring.

Before applying: Keep starting-dose eligibility separate from subsequent titration, response, potassium and renal-function surveillance.

Also check: ENTRESTO: reduced starting dose is not a permanent maintenance cap

Official source

Sacubitril / valsartan tablets (Entresto, adults) - selected U.S. label sections

Product / population
Adult ENTRESTO oral tablets only; no pediatric or sprinkle dosing is supplied.
Renal measure
eGFR in mL/min/1.73 m2

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal starting-dose modification

At eGFR below 30, start at half the usual recommended adult starting dose. For the adult tablet regimen this is sacubitril 24 mg/valsartan 26 mg twice daily. Mild or moderate renal impairment does not require a starting adjustment. Titrate according to the full adult instructions and tolerability.

Safety boundaries

Renal function, potassium and blood pressure require attention. Do not use concurrently with an ACE inhibitor; observe the labeled separation when switching. This is not a pediatric weight-based dose.

Source revision: Revision not captured; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Sacubitril / valsartan tablets (Entresto, adults) - selected U.S. label sections

Adult ENTRESTO oral tablets only; no pediatric or sprinkle dosing is supplied.

Renal method: eGFR in mL/min/1.73 m2
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ENTRESTO

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected adult ENTRESTO starting-dose and monitoring guidance. Pediatric weight/formulation instructions remain outside this card.

Renal method: eGFR, mL/min/1.73 m2; retain the body-surface-area denominator.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

ENTRESTO: reduced starting dose is not a permanent maintenance cap

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dose table scope

ENTRESTO: reduced starting dose is not a permanent maintenance cap

The renal subsection changes the initial dose in severe impairment and then retains titration and kidney/potassium monitoring.

How to use this: Keep starting-dose eligibility separate from subsequent titration, response, potassium and renal-function surveillance.

GlobalRPh RX List - ENTRESTO

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeSacubitril / valsartan tablets (Entresto, adults) - selected U.S. label sectionsGlobalRPh RX List - ENTRESTO
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f

Product and population scope

Adult ENTRESTO oral tablets only; no pediatric or sprinkle dosing is supplied.

RDM32-sacubitril-valsartan-entresto-adult-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Sacubitril / valsartan tablets (Entresto, adults) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult ENTRESTO oral tablets only; no pediatric or sprinkle dosing is supplied.

Renal method: eGFR in mL/min/1.73 m2
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal starting-dose modification

At eGFR below 30, start at half the usual recommended adult starting dose. For the adult tablet regimen this is sacubitril 24 mg/valsartan 26 mg twice daily. Mild or moderate renal impairment does not require a starting adjustment. Titrate according to the full adult instructions and tolerability.

RDM32-sacubitril-valsartan-entresto-adult-1 · Source locator: 2.2; 2.7; 8.7

Safety boundaries

Renal function, potassium and blood pressure require attention. Do not use concurrently with an ACE inhibitor; observe the labeled separation when switching. This is not a pediatric weight-based dose.

RDM32-sacubitril-valsartan-entresto-adult-2 · Source locator: 4; 5; 7

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f
Retrieved
2026-09-05
DailyMed Set ID
000dc81d-ab91-450c-8eae-8eb74e72296f
Renal-function method
eGFR in mL/min/1.73 m2
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
cf9c2b4cc87ab00bf16096df13fd44b417f113f5e14ae6dc9a294da0d1e35e99
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ENTRESTO

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Selected adult ENTRESTO starting-dose and monitoring guidance. Pediatric weight/formulation instructions remain outside this card.

Renal method: eGFR, mL/min/1.73 m2; retain the body-surface-area denominator.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At eGFR <30 mL/min/1.73 m2, start at half the usual recommended starting dose, then titrate as directed by the applicable protocol. Mild or moderate impairment needs no starting-dose adjustment. This is a starting-dose rule, not a permanent half-maintenance-dose ceiling. Monitor creatinine and potassium; clinically significant renal decline may require dose reduction or interruption.

RDM45-rxlist-sacubitril-valsartan-entresto-adult-18edb9197d-C1 · Source locator: Dosage Adjustment for Severe Renal Impairment, lines 101-106; Renal Impairment, lines 311-313; renal/potassium warnings in turn484113view7, lines 237-244.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/entresto-drug/
Retrieved
2026-09-08
Renal-function method
eGFR, mL/min/1.73 m2; retain the body-surface-area denominator.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
036fb34734296b559a1bc41d3a7d1a267804493d0a5775b831df32f871178d2d

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
06c3452010202eb7585ff27647c4700c851873662254effaee762e1669dc7cc4
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report